<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01685619</url>
  </required_header>
  <id_info>
    <org_study_id>AML-MDS 01-2011</org_study_id>
    <nct_id>NCT01685619</nct_id>
  </id_info>
  <brief_title>AML-MDS Novel Prognostic Tests Clinical Study</brief_title>
  <official_title>A Multi-Centre Observational Prospective Cohort Study Involving the Collection of Clinical Information and Biological Specimens for the Evaluation of Novel Prognostic Tests for Myelodysplasia and Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stephen Couban</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terry Fox Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will provide the study specimens (samples of bone marrow and blood) and
      the clinical data for a pan-Canadian collaborative research project developed by the MDS/AML
      Research Consortium. The goal of this project involves the evaluation and potential
      validation of five novel prognostic tests for myelodysplasia (MDS) and/or acute myeloid
      leukemia (AML), as well as an analysis of health economic and socio-ethical implications
      related to the potential introduction of these tests into the clinical setting. The
      over-arching goal is to improve the outcomes of patients with MDS and AML. The primary
      hypothesis is that one or more of the laboratory tests being evaluated in conjunction with
      this study, either alone or in combination with other laboratory tests (either established or
      under investigation in this project), will have statistically significant prognostic value
      either alone or in combination with established clinical risk factors.

      The clinical study will involve the enrollment of 200 adults with AML and 200 adults with MDS
      over a 2.5 year period. Participants will be followed on study for two years. Bone marrow and
      blood specimens will be collected at diagnosis and at other time points as required for the
      development of the five laboratory tests.

      Participants will be assigned to treatment according to local institutional practice and will
      be followed for up to 2 years. Health economic and quality of life questionnaires will be
      administered at key time points. Data will be collected regarding participant
      characteristics, diagnosis, disease features, treatment and clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two of the tests involve a technology called flow cytometry. Both of the flow cytometry tests
      are used to predict whether a person is likely to have a good response to chemotherapy or
      not.

      Three of the tests involve new genetic-based technology. One of these tests is called
      comparative genomic profiling. This test can detect genetic abnormalities that current
      testing methods are not able to detect. Another test involves micro-RNA profiling. The final
      test involves RNA sequencing. The researchers think these tests might be useful in predicting
      how well a person will respond to treatment.

      The novel laboratory tests being evaluated as part of this study are still in the early
      phases of development and cannot be used for clinical decision making. Participants enrolled
      in this study will not be informed regarding their individual results with respect to the
      study tests that are conducted using their biospecimens.

      The following information (data) will be collected regarding study participants: diagnosis,
      results of relevant clinical tests, age, gender, treatment and outcome during the 2 year
      study follow-up period. The study also involves the completion of study questionnaires at six
      different time points over the course of the two year study follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic capacity of the candidate tests (alone and in combination) to predict response to treatment, time to relapse, time to death.</measure>
    <time_frame>Two years following the completion of enrollment.</time_frame>
    <description>For the AML cohort, the candidate prognostic tests will be analyzed with adjustments for following clinical factors: age, white blood cell count at presentation, antecedent hematologic disorder, FLT-3 status, Karnofsky Performance Status (KPS), cytogenetic sub-group (using WHO 2008). For the MDS cohort the candidate prognostic tests will be analyzed with adjustments for following clinical factors: age, KPS, karyotype, bone marrow blast count and number of cytopenias at diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost impact of candidate tests.</measure>
    <time_frame>Two years following the completion of enrollment.</time_frame>
    <description>The cost-effectiveness of the candidate tests for AML and MDS treatment will be projected with the aid of economic simulation models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Societal risks and benefits related to the candidate tests.</measure>
    <time_frame>Two years following the completion of enrollment.</time_frame>
    <description>A comparative analysis of policies and regulations in Canada governing prognostic tests will be undertaken (including tests that utilize RNA and DNA based technologies). In addition, input will be obtained from key stakeholders. This information will be used to develop a set of guidelines and best practices for this type of research.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>AML Cohort</arm_group_label>
    <description>This cohort is comprised of participants who have acute myelogenous leukemia (AML).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDS Cohort</arm_group_label>
    <description>This cohort is comprised of participants who have myelodysplastic syndrome (MDS).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Some of the laboratory tests that will be evaluated as part of this study will utilize RNA
      and/or DNA. There may be biospecimens left over after the work related to this study is
      complete. At the time of consent for the study, participants will be asked to provide consent
      (or decline their consent) regarding the use of leftover specimens (including RNA and DNA)
      for other research. The details regarding this other research are provided in the protocol
      and consent template.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective participants will include patients with known or supsected AML or MDS who are
        being treated and/or assessed at a participating site.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        There are two parts to the study: Part One (Collection of Biospecimens) and Part Two (Two
        year follow-up that includes data collection regarding treatment, outcome and questionnaire
        completion).

        INCLUSION CRITERIA (PART ONE):

        Prospective participants can be included in the study if:

          -  The participant is 18 years of age or older

          -  The participant is suspected to have a new diagnosis of MDS (including CMML) , OR
             suspected to have a new diagnosis of AML excluding acute promyelocytic leukemia (APL),
             OR known to have a diagnosis of MDS (including CMML) confirmed by bone marrow aspirate
             and biopsy no more than one year prior to the date of enrollment AND without
             commencement of definitive therapy prior to enrollment

          -  The participant is scheduled to have a diagnostic or confirmatory bone marrow aspirate
             and biopsy at a participating site, or in the case of prospective participants with an
             established diagnosis of MDS (including CMML), must be able to undergo a bone marrow
             aspirate for the study at the participating site

          -  The participant must be able to read and/or understand spoken English or French so
             that they will be eligible for Part Two of the study

          -  The participant must be able to understand and sign the informed consent form
             applicable to their situation

        EXCLUSION CRITERIA (PART ONE):

        Prospective participants should be excluded from the study if:

          -  The participant has already received definitive therapy for AML or MDS

          -  The participant has a diagnosis of MDS that was confirmed more than one year prior to
             the date of enrollment

        INCLUSION CRITERIA (PART TWO):

        Participants who have been enrolled in Part One will be eligible to participate in the full
        two year study follow-up component if they meet the following criteria:

          -  Confirmed diagnosis of either MDS, CMML or AML (excluding APL)

          -  Sufficient cell count for the MDS/AML Clinical Study requirements as follows:

        For participants with suspected (or known) AML:

        The blast count of the peripheral blood taken at diagnosis must be greater than 1 x10^6
        blast count/mL

          -  It must be possible to earmark for the MDS/AML Study:

          -  3 vials 1.0 x 10^7/mL mononuclear peripheral blood cells

          -  1 vial 0.5 x 10^7/mL mononuclear bone marrow cells

        Cells are to be prepared according to the site's local cell bank procedures so that they
        can be stored and transported to study labs as needed.

        At sites participating in the Hogge Assay:

        In addition to the specimens described above, it must be possible to provide 2 mL of fresh
        bone marrow or 5 mL of fresh peripheral blood with &gt; 1 x 10^6 blast count/mL

        For participants with suspected (or known) MDS:

          -  It must be possible to earmark for the MDS/AML Study:

          -  2 vials 1.0 x 10^7/mL mononuclear peripheral blood cells

          -  2 vials 1.0 x 10^7/mL mononuclear bone marrow cells

        Cells are to be prepared according to the site's local cell bank procedures so that they
        can be stored and transported to study labs as needed.

        EXCLUSION CRITERIA (PART TWO):

        Participants who have been enrolled in Part One will not be eligible to participate in the
        full two year study follow-up component if they:

          -  Do not have sufficient cell count for the MDS/AML Clinical Study requirements as set
             out in Section 11.3

          -  It is confirmed after enrollment that they do not have a diagnosis of MDS, CMML or AML

          -  A diagnosis of APL is confirmed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Couban, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre (formerly Princess Margaret Hospital)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2012</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Stephen Couban</investigator_full_name>
    <investigator_title>Interim Head, Division of Hematology, Director, Blood and Marrow Transplant Program</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>MDS</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Prognostic</keyword>
  <keyword>Economic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

